RAS Mutations Are Not Created Equal
Abstract
Summary: In this issue of Cancer Discovery, Poulin and colleagues apply structural, biochemical, and biological profiling of two mutants of KRAS, one found most frequently in all cancers (G12D) and one found nearly exclusively in colorectal cancer (A146T). They provide compelling evidence that specific mutations will impart different structural and biochemical consequences on KRAS function and that the same KRAS mutation displays tissue-distinct signaling and biological consequences. See related article by Poulin et al., p. 738.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The KRASG12D mutation has intrinsic wildtype and SOS1 guanine exchange activities, while the KRASQ61 mutation has deficiencies in GTP hydrolysis.
“The KRASG12D mutation has an intrinsic wildtype and SOS1 guanine exchange activities while the KRASQ61 mutation has deficiencies in GTP hydrolysis27,30.”
From Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma (2024) · cites this paper as [27]
The KRASG12R mutation is associated with different downstream signaling pathways relative to other KRAS mutations.
“The KRASG12R mutation, which accounts for approximately 15% of the KRAS mutations in pancreatic cancer but less than 1% of the KRAS mutations in lung cancer, was reported to be associated with different downstream signaling pathways relative to other KRAS mutations27.”
From Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma (2024) · cites this paper as [27]
The citation lists haven’t been fetched yet
References 10 · Cited by 35
- Authors
- Hobbs, G. A., & Der, C. J.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Venue
- Cancer Discovery
- Published
- 2019-06-01
- Volume
- 9
- Issue
- 6
- Pages
- 696-698
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2947624034
- Cited by
- 35
- References
- 10
- Citations by year
- 2026: 1 · 2025: 8 · 2024: 4 · 2023: 2 · 2022: 4 · 2021: 5 · 2020: 9 · 2019: 2
- FWCI
- 1.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- KRAS mutation, G12D mutation, tissue-specific signaling, colorectal cancer, oncogenic KRAS
- MeSH terms
- Humans, Mutation, Oncogenes, Colorectal Neoplasms, Signal Transduction, Proto-Oncogene Proteins p21(ras), Carcinogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
